Invivyd, Inc.
About Invivyd, Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $53.4M
- Net income
- -$52.5M
- Total assets
- $276.9M
- Market cap
- $303.4M
- Operating margin
- -104.0%
- Net margin
- -98.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $53.4M
- Operating expenses
- $109.0M
- Operating income
- -$55.6M
- Income tax
- $0
- Net income
- -$52.5M
- EPS (basic)
- $-0.30
- EPS (diluted)
- $-0.30
Balance sheet
- Total assets
- $276.9M
- Current assets
- $247.5M
- Total liabilities
- $35.3M
- Current liabilities
- $34.2M
- Shareholders’ equity
- $241.5M
Cash flow
- Operating cash flow
- -$58.1M
- Investing cash flow
- -$155.0K
- Financing cash flow
- $215.6M
- Net cash flow
- $157.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $303.4M
- EPS (diluted)
- $-0.3
- Shares outstanding
- 337.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 6, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $52.5M in FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Invivyd, Inc..
Write a review
News about Invivyd, Inc.
News & sentiment via Polygon.io
